Cargando…

Androgen deprivation promotes neuroendocrine differentiation and angiogenesis through CREB-EZH2-TSP1 pathway in prostate cancers

The incidence of aggressive neuroendocrine prostate cancers (NEPC) related to androgen-deprivation therapy (ADT) is rising. NEPC is still poorly understood, such as its neuroendocrine differentiation (NED) and angiogenic phenotypes. Here we reveal that NED and angiogenesis are molecularly connected...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yan, Zheng, Dayong, Zhou, Ting, Song, Haiping, Hulsurkar, Mohit, Su, Ning, Liu, Ying, Wang, Zheng, Shao, Long, Ittmann, Michael, Gleave, Martin, Han, Huanxing, Xu, Feng, Liao, Wangjun, Wang, Hongbo, Li, Wenliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172226/ https://www.ncbi.nlm.nih.gov/pubmed/30287808 http://dx.doi.org/10.1038/s41467-018-06177-2

Ejemplares similares

GRK3 is a direct target of CREB activation and regulates neuroendocrine differentiation of prostate cancer cells
por: Sang, Meixiang, et al.
Publicado: (2016)

Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1/EZH2-mediated downregulation of REST
por: Li, Wenliang, et al.
Publicado: (2023)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
por: Hwang, Justin H., et al.
Publicado: (2019)

Molecular Links Between Angiogenesis and Neuroendocrine Phenotypes in Prostate Cancer Progression
por: Wang, Zheng, et al.
Publicado: (2020)

CKB inhibits epithelial-mesenchymal transition and prostate cancer progression by sequestering and inhibiting AKT activation
por: Wang, Zheng, et al.
Publicado: (2021)

Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation
por: Lipianskaya, Julia, et al.
Publicado: (2014)

Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2022)

Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer
por: Chen, Xuanrong, et al.
Publicado: (2023)

Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression
por: Zhao, Yicheng, et al.
Publicado: (2019)

Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
por: Karavasilis, Vasilis, et al.
Publicado: (2005)

Involvement of TSP1 and MMP9/NGAL in Angiogenesis during Orthodontic Periodontal Remodeling
por: Surlin, Petra, et al.
Publicado: (2014)

Persistence of senescent prostate cancer cells following prolonged neoadjuvant androgen deprivation therapy
por: Blute, Michael L., et al.
Publicado: (2017)

Inhibition of angiogenesis by arsenic trioxide via TSP-1–TGF-β1-CTGF–VEGF functional module in rheumatoid arthritis
por: Zhang, Juan, et al.
Publicado: (2017)

HAM/TSP introduction: systematic review of HAM/TSP clinical trials
por: Anderson, Rebecca, et al.
Publicado: (2014)

Better Understanding the Timing Of Androgen Deprivation Trial Outcomes: Impacts of Prior Androgen Deprivation Therapy
por: Stensland, Kristian D, et al.
Publicado: (2022)

Computer Simulation of TSP1 Inhibition of VEGF–Akt–eNOS: An Angiogenesis Triple Threat
por: Bazzazi, Hojjat, et al.
Publicado: (2018)

The effect of continuous androgen deprivation treatment on prostate cancer patients as compared with intermittent androgen deprivation treatment
por: Ku, Ja Yoon, et al.
Publicado: (2015)

Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
por: Decker, Keith F., et al.
Publicado: (2012)

Androgen deprivation and cognition in prostate cancer
por: Salminen, E, et al.
Publicado: (2003)

Androgen Deprivation Therapy and Cardiovascular Risk
por: Mourmouris, Panagiotis, et al.
Publicado: (2012)

Metabolic effects of androgen deprivation therapy
por: Choi, See Min, et al.
Publicado: (2015)

Cardiovascular Toxicities of Androgen Deprivation Therapy
por: Challa, Azariyas A., et al.
Publicado: (2021)

CARDIOVASCULAR DISEASES AND ANDROGEN DEPRIVATION THERAPY
por: Boban, Marko
Publicado: (2019)

Cardiovascular Toxicity of Androgen Deprivation Therapy
por: Boland, Julia, et al.
Publicado: (2021)

Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors
por: Taraboletti, Giulia, et al.
Publicado: (2010)

HAM/TSP in relatives of HAM/TSP cases and in relatives of asymptomatic HTLV-1 carriers
por: Alvarez, Carolina, et al.
Publicado: (2014)

TSP: coaching development teams
por: Humphrey, Watts S
Publicado: (2006)

Managing HAM/TSP with Fampridine
por: Menna-Barreto, M Marcio
Publicado: (2014)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
por: Chen, Mengqian, et al.
Publicado: (2010)

Impact of Androgen Deprivation on Oxidative Stress and Antioxidant Status in Nigerian Patients With Prostate Cancer Undergoing Androgen Deprivation Therapy
por: Bassey, Iya Eze, et al.
Publicado: (2020)

Modeling Androgen Deprivation Therapy–Induced Prostate Cancer Dormancy and Its Clinical Implications
por: Dong, Xin, et al.
Publicado: (2022)

The N-Terminal Domain of Thrombospondin-1: a Key for the Dual Effect of TSP-1 in Angiogenesis and Cancer Progression?
por: Morandi, Verônica
Publicado: (2009)

Prostate cancer, insulin, and androgen deprivation therapy
por: Stattin, P, et al.
Publicado: (2003)

Androgen deprivation therapy increases brain ageing
por: Plata-Bello, Julio, et al.
Publicado: (2019)

Androgen Deprivation Therapy–Induced Cardiovascular Disease
por: Dhanushkodi, Manikandan
Publicado: (2016)

Lacrimal sac adenocarcinoma managed with androgen deprivation
por: Abramson, David H., et al.
Publicado: (2020)

Androgen deprivation therapy and the risk of subsequent keratitis
por: Liu, Dai-Wei, et al.
Publicado: (2020)

Duration of androgen deprivation therapy with maximum androgen blockade for localized prostate cancer
por: Fujimoto, Naohiro, et al.
Publicado: (2011)

Inhibition of EZH2 prevents fibrosis and restores normal angiogenesis in scleroderma
por: Tsou, Pei-Suen, et al.
Publicado: (2019)

Transcription factor Creb3l1 maintains proteostasis in neuroendocrine cells
por: Greenwood, Mingkwan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_khi0lingbpl1gecsmivjn6ucma